Zai Lab and Entasis Therapeutics Announce Positive Topline Results for Sulbactam-Durlobactam (SUL-DUR) from Phase 3 ATTACK Trial - TC Read more about Zai Lab and Entasis Therapeutics Announce Positive Topline Results for Sulbactam-Durlobactam (SUL-DUR) from Phase 3 ATTACK Trial - TC
Zai Lab Appoints Scott Morrison to its Board of Directors - TC Read more about Zai Lab Appoints Scott Morrison to its Board of Directors - TC
Zai Lab Announces Upcoming Presentations in October Investor Conferences - TC Read more about Zai Lab Announces Upcoming Presentations in October Investor Conferences - TC
Zai Lab Announces Margetuximab Achieved Primary Objective in Bridging Study in Advanced HER2+ Breast Cancer in Greater China - TC Read more about Zai Lab Announces Margetuximab Achieved Primary Objective in Bridging Study in Advanced HER2+ Breast Cancer in Greater China - TC
Zai Lab Partner Turning Point Therapeutics Granted Breakthrough Therapy Designation for Repotrectinib Treatment in Patients With NTRK-Positive, TKI-Pretreated Advanced Solid Tumors - TC Read more about Zai Lab Partner Turning Point Therapeutics Granted Breakthrough Therapy Designation for Repotrectinib Treatment in Patients With NTRK-Positive, TKI-Pretreated Advanced Solid Tumors - TC
Zai Lab and Novocure Announce Last Patient Enrolled in Phase 2 Pilot Trial of Tumor Treating Fields Plus Chemotherapy as First-Line Treatment in Gastric Cancer in China - TC Read more about Zai Lab and Novocure Announce Last Patient Enrolled in Phase 2 Pilot Trial of Tumor Treating Fields Plus Chemotherapy as First-Line Treatment in Gastric Cancer in China - TC
Zai Lab Holds Virtual Research and Development Day - TC Read more about Zai Lab Holds Virtual Research and Development Day - TC
Zai Lab Expands U.S. Operations to Join the Cambridge Biotechnology Community - TC Read more about Zai Lab Expands U.S. Operations to Join the Cambridge Biotechnology Community - TC
Zai Lab Announces Breakthrough Therapy Designation Granted for Bemarituzumab (FPA144) in China - TC Read more about Zai Lab Announces Breakthrough Therapy Designation Granted for Bemarituzumab (FPA144) in China - TC
Zai Lab to Host Virtual Research and Development Day on September 22, 2021 - TC Read more about Zai Lab to Host Virtual Research and Development Day on September 22, 2021 - TC